The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC Sept 2021 | Emerging frontline strategies in ES-SCLC
Qing Zhou, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, describes her presentation at the World Conference on Lung Cancer (WCLC) 2021, which provides an overview of emerging first-line treatment strategies in extensive-stage small cell lung cancer (ES-SCLC). Current standard of care for ES-SCLC is chemotherapy plus PD-L1 immunotherapy, however there are currently no definitive biomarkers to predict the benefit of immunotherapy. Dr Zhou highlights translational work that sought to define four molecular subtypes of SCLC, as well as the promise of large, ongoing biomarker-driven clinical trials that could impact clinical practice in the future. This interview took place at the WCLC 2021.
